Replies to post #417826 on ORIONS Money Stocks

[Mark]

$SNSS from last PR ->

"We began 2019 by announcing the move into the 100 mg cohort for our Phase 1b/2 trial of vecabrutinib, an important milestone as we continue to believe that 100 -- 300 mg will be the potentially therapeutic dose levels," said Dayton Misfeldt , Interim Chief Executive Officer of Sunesis. "To date, we have seen an encouraging safety profile, evidence of pharmacodynamic activity and some improvements in clinical symptoms in CLL and other B cell cancer patients both with and without BTK C481 mutations. We are targeting an update on our ongoing vecabrutinib trial at the European Hematology Association Congress (EHA) in June 2019 . In addition, in January, we completed an equity offering with leading biotechnology investors that extends our runway through important clinical milestones."

What's not to love here, perfect swing set-up into June, could very well be $2+, look where it came down from....and yes, they do have a handful of presentations they are doing over the next few weeks.